ALTH - Lost about 15% on this announcement in the afternoon and I decided to enter a small position. Based on what I can see, even if Istodax succeeds in PTCL, Folotyn appears to have a much better safety profile and also can be administered easier and CELG's acquisition appears to reinforce the market value in PTCL and CTCL.
Market Data 
Markets 
AI
